Literature DB >> 28887040

Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.

Yu-Jin Kim1, Eun-Ju Ko1, Min-Chul Kim1, Yu-Na Lee1, Ki-Hye Kim1, Yu-Jin Jung1, Sang-Moo Kang2.   

Abstract

Although neuraminidase (NA) is the second major viral glycoprotein of influenza virus, its immune mechanism as a vaccine target has been less considered. Here we compared the properties of antibodies and the efficacy of cross protection by N1 and N2 NA proteins, inactivated split influenza vaccines (split), and tandem repeat extracellular domain M2 on virus-like particles (M2e5x VLP). Anti-NA immune sera could confer better cross-protection against multiple heterologous influenza viruses correlating with NA inhibition activity compared to split vaccine immune sera. Whereas split vaccine was superior to NA in conferring homologous protection. NA and M2e immune sera each showed comparable survival protection. Protective efficacy by NA immune sera was lower in Fc receptor common γ-chain deficient mice but comparable in C3 complement deficient mice compared to that in wild type mice, suggesting a role of Fc receptor in NA immunity.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Influenza virus; M2e; Neuraminidase; Split vaccines

Mesh:

Substances:

Year:  2017        PMID: 28887040      PMCID: PMC5636684          DOI: 10.1016/j.bbrc.2017.09.011

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

1.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

2.  Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

Authors:  David J DiLillo; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

3.  Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.

Authors:  Arnold S Monto; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Merry Liu; Weimin Zhong; Min Levine; Jacqueline M Katz; Suzanne E Ohmit
Journal:  J Infect Dis       Date:  2015-04-08       Impact factor: 5.226

4.  Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.

Authors:  Eun-Ju Ko; Young-Tae Lee; Ki-Hye Kim; Youri Lee; Yu-Jin Jung; Min-Chul Kim; Yu-Na Lee; Taeuk Kang; Sang-Moo Kang
Journal:  J Immunol       Date:  2016-11-23       Impact factor: 5.422

5.  Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.

Authors:  Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Hye Suk Hwang; Jong Seok Lee; Ki-Hye Kim; Sang-Moo Kang
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

6.  Universal anti-neuraminidase antibody inhibiting all influenza A subtypes.

Authors:  Tracey M Doyle; Anwar M Hashem; Changgui Li; Gary Van Domselaar; Louise Larocque; Junzhi Wang; Daryl Smith; Terry Cyr; Aaron Farnsworth; Runtao He; Aeron C Hurt; Earl G Brown; Xuguang Li
Journal:  Antiviral Res       Date:  2013-09-30       Impact factor: 5.970

7.  Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

Authors:  Teddy John Wohlbold; Raffael Nachbagauer; Haoming Xu; Gene S Tan; Ariana Hirsh; Karl A Brokstad; Rebecca J Cox; Peter Palese; Florian Krammer
Journal:  mBio       Date:  2015-03-10       Impact factor: 7.867

Review 8.  In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.

Authors:  Teddy John Wohlbold; Florian Krammer
Journal:  Viruses       Date:  2014-06-23       Impact factor: 5.048

9.  Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.

Authors:  Caitlin E Mullarkey; Mark J Bailey; Diana A Golubeva; Gene S Tan; Raffael Nachbagauer; Wenqian He; Kyle E Novakowski; Dawn M Bowdish; Matthew S Miller; Peter Palese
Journal:  mBio       Date:  2016-10-04       Impact factor: 7.867

Review 10.  New vaccines against influenza virus.

Authors:  Young-Tae Lee; Ki-Hye Kim; Eun-Ju Ko; Yu-Na Lee; Min-Chul Kim; Young-Man Kwon; Yinghua Tang; Min-Kyoung Cho; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Clin Exp Vaccine Res       Date:  2013-12-18
View more
  11 in total

1.  Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.

Authors:  Ki-Hye Kim; Young-Tae Lee; Soojin Park; Yu-Jin Jung; Youri Lee; Eun-Ju Ko; Yu-Jin Kim; Xuguang Li; Sang-Moo Kang
Journal:  Virology       Date:  2019-07-08       Impact factor: 3.616

2.  Bivalent vaccination with NA1 and NA2 neuraminidase virus-like particles is protective against challenge with H1N1 and H3N2 influenza A viruses in a murine model.

Authors:  Zach Menne; Vasilis C Pliasas; Richard W Compans; Sheniqua Glover; Constantinos S Kyriakis; Ioanna Skountzou
Journal:  Virology       Date:  2021-08-05       Impact factor: 3.513

3.  Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.

Authors:  Michael S Piepenbrink; Aitor Nogales; Madhubanti Basu; Christopher F Fucile; Jane L Liesveld; Michael C Keefer; Alexander F Rosenberg; Luis Martinez-Sobrido; James J Kobie
Journal:  mBio       Date:  2019-03-12       Impact factor: 7.867

4.  Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies.

Authors:  E R Job; T Ysenbaert; A Smet; A Van Hecke; L Meuris; H Kleanthous; X Saelens; T U Vogel
Journal:  mBio       Date:  2019-10-22       Impact factor: 7.867

5.  Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.

Authors:  Wenling Wang; Baoying Huang; Xiuping Wang; Wenjie Tan; Li Ruan
Journal:  Virol Sin       Date:  2019-06-25       Impact factor: 4.327

Review 6.  Influenza Neuraminidase: A Neglected Protein and Its Potential for a Better Influenza Vaccine.

Authors:  Luca T Giurgea; David M Morens; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Vaccines (Basel)       Date:  2020-07-23

7.  Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin.

Authors:  Bo Ryoung Park; Ki-Hye Kim; Tatiana Kotomina; Min-Chul Kim; Young-Man Kwon; Subbiah Jeeva; Yu-Jin Jung; Noopur Bhatnagar; Irina Isakova-Sivak; Daria Mezhenskaya; Larisa Rudenko; Bao-Zhong Wang; Sang-Moo Kang
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

8.  BCG Cell Wall Skeleton As a Vaccine Adjuvant Protects Both Infant and Old-Aged Mice from Influenza Virus Infection.

Authors:  Ki-Hye Kim; Young-Tae Lee; Yoonsuh Park; Eun-Ju Ko; Yu-Jin Jung; Yu-Jin Kim; Eun-Kyeong Jo; Sang-Moo Kang
Journal:  Biomedicines       Date:  2021-05-05

Review 9.  Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections.

Authors:  Shamus P Keeler; Julie M Fox
Journal:  Viruses       Date:  2021-05-31       Impact factor: 5.048

Review 10.  Protective Antibodies Against Influenza Proteins.

Authors:  Herbey O Padilla-Quirarte; Delia V Lopez-Guerrero; Lourdes Gutierrez-Xicotencatl; Fernando Esquivel-Guadarrama
Journal:  Front Immunol       Date:  2019-07-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.